Assembly Biosciences, Inc
ASMBAssembly Biosciences, Inc. (ASMB) is a biotechnology company focused on developing therapies for viral infections and liver diseases. The company utilizes innovative approaches, including proprietary core platform technologies, to develop treatments for hepatitis B, other chronic viral infections, and microbiome-related conditions. Founded with a focus on advancing fundamental scientific research into therapeutic solutions, Assembly Biosciences aims to address unmet medical needs with its antiviral and microbiome-based therapies.
Company News
Assembli has been selected to design and produce the Big Ten Conference's first-ever fan experience at Fanatics Fest NYC (July 16-19, 2026), making the Big Ten the first collegiate conference to participate in the event. The activation will feature the Heisman Trophy, CFP National Championship Trophy, interactive games, and fan engagement activit...
Assembly Biosciences announced that its Chief Medical Officer, Anuj Gaggar, MD, PhD, will present at the Bank of America Securities 2026 Global Health Care Conference on May 13, 2026. The company also highlighted positive Phase 1b data for its helicase-primase inhibitors ABI-5366 and ABI-1179 for recurrent genital herpes treatment, with additiona...
Assembly Biosciences reported Q1 2026 financial results with cash reserves of $226.6 million, sufficient to fund operations into 2028. The company completed Phase 1b studies for herpes candidates ABI-5366 and ABI-1179 (licensed to Gilead) and chronic toxicology studies for hepatitis delta virus candidate ABI-6250, with Phase 2 initiation expected...
Assembly's NeosAI, built on Microsoft Azure AI Foundry, has demonstrated significant time savings and workflow automation for law firms, with advanced natural language processing and enterprise-grade security.
Insiders have been purchasing shares in American Software, Assembly Biosciences, and Tile Shop Holdings, indicating their confidence in the companies' prospects.
